Helio Vision
Helio Vision develops a therapy for rare, fibroproliferative disorders that lead to abnormal scarring and blindness after retina surgery.
Launch date
Market cap
-
Enterprise valuation
€23m (Public information from Feb 2019)
Lexington Kentucky (HQ)
Date | Investors | Amount | Round |
---|---|---|---|
N/A | $260k | Seed | |
$25.0m Valuation: $25.0m | Acquisition | ||
Total Funding | €236k |
Recent News about Helio Vision
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.